Drugs / Compliance Tips and Tools / Part D plan sponsors to watch for provider fraud

Why This Topic Matters

The topic matters for compliance teams and Part D stakeholders because it highlights the types of provider behavior and transaction patterns CMS expects plans and contractors to review. It helps readers understand the scope of oversight expected in Medicare drug benefit programs and the general categories of issues that may trigger reporting or further review.

Article Sections

1. CMS guidance for Part D sponsor oversight

   Overview of CMS expectations for Part D plan sponsors and how they are expected to support fraud detection through compliance program activity and data review.

2. Provider activities and patterns under review

   Discussion of the broad categories of provider and prescribing behavior that sponsors are expected to monitor, including documentation consistency, prescribing trends, and coordination issues across benefit programs.

3. MEDIC priorities and compliance monitoring

   Summary of the areas CMS says Medicare Drug Integrity Contractors should focus on, including rebate oversight, co-pay handling, and drug utilization review.

4. Related compliance resources

   Brief note pointing readers to related Medicare compliance material referenced by the article.